Lung Cancer Clinical Trial
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed during surgery and may kill any remaining tumor cells following surgery.
PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and surgery in treating patients who have newly diagnosed locally advanced non-small cell lung cancer.
Full Description
OBJECTIVES:
Determine the complete resection rate and toxic death rate of patients with locally advanced non-small cell lung cancer treated with paclitaxel, carboplatin, and radiotherapy followed by surgical resection and adjuvant paclitaxel and carboplatin.
Determine the survival, event-free survival, and incidence of pathologic complete remission of patients treated with this regimen.
Determine the protocol completion rate (CR) of patients treated with this regimen.
Determine the feasibility and toxicity of this regimen in these patients.
Determine the pathologic response rate/downstaging, pathologic near CR rate, freedom from distant metastasis rate, and freedom from local regional failure rate of patients treated with this regimen.
OUTLINE: Patients receive induction therapy comprising radiotherapy 5 days a week for 5.5-6 weeks and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
Within 1-3 weeks after completion of induction therapy, patients undergo restaging. Patients with resectable disease undergo surgical resection within 4-8 weeks after induction therapy. Patients with unresectable disease undergo additional radiotherapy 5 days a week for 3 weeks and receive paclitaxel and carboplatin as in induction therapy on days 1, 8, and 15.
Within 4-12 weeks after surgery or additional chemoradiotherapy, patients receive adjuvant therapy comprising paclitaxel and carboplatin as in induction therapy on day 1. Adjuvant treatment repeats every 4 weeks for 3 courses.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 57 patients will be accrued for this study within 4 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed, newly diagnosed, unilateral primary non-small cell lung cancer (NSCLC)
Must have involvement of the superior sulcus, chest wall, or mediastinum
Must have at least 1 of the following:
Locally advanced Pancoast tumors with no documented mediastinal or supraclavicular nodal involvement (T3-T4, N0-1)
Resectable chest wall disease (T3, N0-1)
Marginally resectable T4, N0-1, or NX central NSCLC
N2 patients who are potentially resectable after induction chemoradiotherapy
No evidence of extrathoracic spread to liver, adrenals, brain, or bone
No evidence of supraclavicular nodes, malignant pleural or pericardial effusions, or distant metastases
PATIENT CHARACTERISTICS:
Age
18 and over
Performance status
Karnofsky 70-100%
Life expectancy
Not specified
Hematopoietic
Absolute neutrophil count at least 2,000/mm^3
Platelet count at least 100,000/mm^3
Hepatic
Bilirubin no greater than 1.5 mg/dL
SGOT no greater than 3 times upper limit of normal
Renal
Creatinine no greater than 2.0 mg/dL
Cardiovascular
No superior vena cava syndrome
No myocardial infarction within the past 6 months
No active uncontrolled congestive heart failure
No active uncontrolled arrhythmia within the past 6 months
Pulmonary
FEV1 at least 800 mL
Other
No other active invasive malignancy requiring therapy within the past 2 years
No ongoing need for adjuvant therapy
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for at least 3 months after study entry
PRIOR CONCURRENT THERAPY:
Biologic therapy
Not specified
Chemotherapy
Not specified
Endocrine therapy
Not specified
Radiotherapy
No prior pelvic or thoracic radiotherapy
Surgery
See Disease Characteristics
Other
Concurrent beta blockers, digitalis derivatives, or channel-blocking agents allowed provided cardiac conditions are stable
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19111, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.